TCM
AGIO icon

Tekla Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Tekla Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-186,964
Closed -$6.54M – 202
2020
Q3 		$6.54M Hold
186,964
– – 0.25% 89
2020
Q2 		$10M Hold
186,964
– – 0.38% 56
2020
Q1 		$6.63M Sell
186,964
-29,444
-14% -$1.36M 0.3% 67
2019
Q4 		$10.3M Buy
216,408
+74,191
+52% +$2.8M 0.39% 56
2019
Q3 		$4.61M Sell
142,217
-3,125
-2% -$129K 0.2% 86
2019
Q2 		$7.25M Buy
145,342
+53,566
+58% +$2.86M 0.3% 75
2019
Q1 		$6.19M Buy
91,776
+42,751
+87% +$2.49M 0.25% 84
2018
Q4 		$2.26M Buy
49,025
+15,155
+45% +$935K 0.1% 122
2018
Q3 		$2.61M Buy
33,870
+31,060
+1,105% +$2.5M 0.09% 131
2018
Q2 		$237K Hold
2,810
– – 0.01% 175
2018
Q1 		$230K Buy
+2,810
New +$217K 0.01% 184
2015
Q2 		– Sell
-100,300
Closed -$9.46M – 118
2015
Q1 		$9.46M Buy
100,300
+54,100
+117% +$6.06M 0.37% 64
2014
Q4 		$5.18M Buy
46,200
+11,200
+32% +$1,000K 0.24% 70
2014
Q3 		$2.15M Buy
+35,000
New +$1.51M 0.1% 103

Other funds holding AGIO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Tekla Capital Management's AGIO Position: Q4 2020 in Review

Tekla Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q4 2020, closing a stake of 186,964 shares — an estimated $6.54M sold.

Tekla Capital Management first reported a position in AGIO in Q3 2014 and held it in 14 quarters. The position peaked at $10.3M in Q4 2019. 200 funds tracked by Wall St. Rank hold AGIO as of Q4 2020.

  • Tekla Capital Management reported no remaining Agios Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Tekla Capital Management sold 186,964 Agios Pharmaceuticals shares in Q4 2020, an estimated $6.54M.
  • Tekla Capital Management first reported a position in Agios Pharmaceuticals in Q3 2014 and held it in 14 quarters.
  • Tekla Capital Management's Agios Pharmaceuticals position peaked at $10.3M in Q4 2019.
  • 200 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2020.

Based on Tekla Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.